State Street’s Telomir Pharmaceuticals TELO Stock Holding History

State Street’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75K	Hold	58,600	–	–	﹤0.01%	4005
2026 Q1	$76.2K	Hold	58,600	–	–	﹤0.01%	4074
2025 Q4	$77.9K	Hold	58,600	–	–	﹤0.01%	4088
2025 Q3	$81.5K	Sell	58,600 -3,000	-5%	-$4.52K	﹤0.01%	4084
2025 Q2	$77K	Sell	61,600 -64,073	-51%	-$148K	﹤0.01%	4019
2025 Q1	$406K	Buy	125,673 +9,879	+9%	+$43.2K	﹤0.01%	3636
2024 Q4	$477K	Buy	115,794 +79,700	+221%	+$376K	﹤0.01%	3628
2024 Q3	$232K	Buy	36,094 +17,967	+99%	+$87.6K	﹤0.01%	3791
2024 Q2	$87.2K	Buy	+18,127	New	+$113K	﹤0.01%	4045

Other funds holding TELO

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

WIA

World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

State Street's TELO Position: Q2 2026 in Review

State Street held its Telomir Pharmaceuticals (TELO) position steady in Q2 2026 at 58,600 shares worth $75K. The position accounts for ﹤0.01% of the portfolio, ranked #4005.

State Street first reported a position in TELO in Q2 2024 and has held it in 9 quarters since. The position peaked at $477K in Q4 2024. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

State Street held 58,600 shares of Telomir Pharmaceuticals worth $75K as of Q2 2026.
State Street left its Telomir Pharmaceuticals share count unchanged in Q2 2026.
Telomir Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4005 holding.
State Street first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
State Street's Telomir Pharmaceuticals position peaked at $477K in Q4 2024.
33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.